Literature DB >> 6451162

Increased fibrinopeptide A formation and thromboxane A2 production in patients with ischemic heart disease: relationships to coronary pathoanatomy, risk factors, and clinical manifestations.

G G Neri Serneri, G F Gensini, R Abbate, C Mugnaini, S Favilla, C Brunelli, S Chierchia, O Parodi.   

Abstract

In 98 patients with ischemic heart disease (IHD), independent of their clinical status (previous myocardial infarction, spontaneous angina or effort angina), a hypercoagulable state (indicated by significant elevation of fibrinopeptide A plasma level) and an increased platelet biologic activity were observed. Moreover, plasma fibrinopeptide A concentration and platelet aggregation were remarkably higher in patients with frequently occurring spontaneous clinical manifestations (active disease) than in IHD patients with relatively quiescent symptoms. Abnormalities of blood clotting and platelet changes were not significantly altered by the presence of severity of coronary angiographic fixed obstruction in IHD. Multiple regression analysis indicated that hypercoagulability and increased platelet biologic activity were not a consequence of differences in risk factor patterns in IHD patients compared to control subjects.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6451162     DOI: 10.1016/0002-8703(81)90665-7

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  8 in total

1.  Percutaneous transluminal coronary angioplasty of one vessel for refractory unstable angina pectoris: efficacy in single and multivessel disease.

Authors:  B Sharma; R P Wyeth; G S Kolath; H J Gimenez; J A Franciosa
Journal:  Br Heart J       Date:  1988-03

Review 2.  The thromboxane synthase and receptor signaling pathway in cancer: an emerging paradigm in cancer progression and metastasis.

Authors:  Prasanna Ekambaram; Wanyu Lambiv; Rosanna Cazzolli; Anthony W Ashton; Kenneth V Honn
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

3.  Thromboxane receptor density is increased in human cardiovascular disease with evidence for inhibition at therapeutic concentrations by the AT(1) receptor antagonist losartan.

Authors:  S D Katugampola; A P Davenport
Journal:  Br J Pharmacol       Date:  2001-12       Impact factor: 8.739

4.  Enhanced thrombolytic efficacy and reduction of infarct size by simultaneous infusion of streptokinase and heparin.

Authors:  G Melandri; A Branzi; F Semprini; V Cervi; N Galiè; B Magnani
Journal:  Br Heart J       Date:  1990-08

5.  Novel Antithrombotic Strategies for the Treatment of Coronary Artery Thrombosis: A Critical Appraisal.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

6.  Plasma malondialdehyde in coronary patients and in "normal" people at rest and after exercise.

Authors:  P Avogaro; G B Bon; G Cazzolato; G Gualandi; G Caturelli
Journal:  Tex Heart Inst J       Date:  1986-09

7.  The effect of prolonged treatment with sulphinpyrazone on thromboxane A2 and prostacyclin in man.

Authors:  L Viinikka; J Toivanen; O Ylikorkala
Journal:  Br J Clin Pharmacol       Date:  1982-09       Impact factor: 4.335

8.  Thrombin and plasmin activity in coronary artery disease.

Authors:  M Small; G D Lowe; J T Douglas; I Hutton; A R Lorimer; C D Forbes
Journal:  Br Heart J       Date:  1988-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.